# Nexalin Technology, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Nexalin Technology, Inc.). ## Overview Nexalin Technology, Inc. develops and commercializes non-invasive electrotherapy devices used in mental health and related therapeutic applications. The company sells devices, consumable supplies, and licensing or treatment-fee arrangements tied to customer use of its systems, with activity in the United States and overseas markets. ## Products & services • Non-invasive electrotherapy devices • Boards, electrodes, and patient cables • Licensing agreements for device use • Treatment-fee arrangements based on usage • Supplies and related consumables - **Devices** (35%) — Electrotherapy systems sold for therapeutic use in clinical and other settings. - **Equipment and Consumables** (40%) — Boards, electrodes, patient cables, and other hardware used with the device. - **Licensing Fees** (15%) — Monthly licensing arrangements that allow customers to use the technology. - **Treatment Fees and Supplies** (10%) — Usage-based treatment fees and recurring supply sales tied to installed systems. - Non-invasive electrotherapy devices - Boards, electrodes, and patient cables - Licensing agreements for device use - Treatment-fee arrangements based on usage - Supplies and related consumables ## Customers Nexalin sells to customers that operate or distribute therapeutic devices, including healthcare-related users and overseas buyers of equipment and systems. Its revenue model combines one-time equipment sales with recurring licensing and treatment-based fees, so customers buy both for access to the technology and for ongoing use of the device platform. - **Healthcare and therapeutic users** (primary) — Buy devices and related supplies for therapeutic use and ongoing patient treatments. - **International equipment customers** (primary) — Purchase boards, devices, and accessories for deployment outside the U.S. - **License and treatment-fee customers** (secondary) — Pay recurring fees for access to the technology and for each treatment performed. - Healthcare customers using the device in treatment settings - Overseas buyers purchasing boards, devices, and accessories - Licensees paying monthly fees to use the technology - Customers paying per-treatment fees based on device usage - Users buying consumables for installed systems ## Geography The company serves customers in the United States and also sells devices and equipment overseas. Reported revenue disclosures specifically mention shipments to China and a prior device sale to Oman, showing that international transactions can materially affect period-to-period results. - United States is the core servicing market - Overseas sales include devices and equipment - China was a notable destination for board shipments - Oman was cited for a prior device sale - International mix can shift revenue by quarter ## Strategy Nexalin’s strategy centers on expanding commercialization of its device platform, including overseas sales, while continuing to serve existing U.S. customers. The company also emphasizes intellectual property protection, reimbursement coverage, and maintaining product safety and regulatory acceptance, all of which are important for adoption in healthcare markets. - **Commercialize overseas markets** (short-term) — International sales provide a path to revenue while U.S. approval and reimbursement are developed. - **Obtain U.S. approval and reimbursement support** (medium-term) — U.S. market access and coverage are key to broader adoption in healthcare settings. - **Protect intellectual property and product safety** (long-term) — Defending the technology and maintaining safety are central to competitive positioning and adoption. - Expand overseas device and equipment sales - Serve existing U.S. customers while broadening commercialization - Pursue U.S. approval for device sales - Protect intellectual property around the technology - Secure reimbursement and healthcare coverage ## Risks Nexalin faces commercialization risk because adoption depends on regulatory approval, reimbursement, and competition from other therapies. The business is also exposed to foreign trade and tariff issues because it imports components and exports products, while its small scale and recurring operating losses increase financing and going-concern risk. - **Regulatory approval risk** [high] — U.S. device sales depend on obtaining and maintaining approval for the product. - **Reimbursement and coverage risk** [high] — Healthcare adoption can be limited if payers do not cover the therapy adequately. - **Competition from alternative therapies** [medium] — Customers may choose other treatment modalities with stronger clinical or economic support. - **Tariff and trade exposure** [high] — Imported components and exported products can be affected by tariffs or retaliatory trade actions. - **Going-concern and financing risk** [critical] — The company has limited cash resources and has relied on equity funding to support operations. - U.S. approval and reimbursement remain key commercialization hurdles - Competition from other therapies can limit adoption - Tariffs and trade rules can affect imported parts and exports - Foreign sales create exposure to country-specific demand swings - Ongoing losses and cash needs increase financing risk ## Accounting Revenue recognition is important because Nexalin earns revenue from device sales, supplies, licensing fees, and treatment-based arrangements, each of which may be recognized differently. Investors should also watch quarter-to-quarter mix changes, since higher-margin device or licensing revenue can be replaced by lower-margin equipment sales, affecting reported gross profit and comparability. - **Revenue recognition across devices, licensing, and treatment fees** — Affects reported revenue timing and quarterly comparability - **Revenue mix and gross margin variability** — Can move gross profit materially from period to period - **Fair value changes on short-term investments** — Affects comprehensive loss and equity - **Going-concern assessment** — Important for evaluating solvency and disclosure risk - Multiple revenue streams require different recognition judgments - Licensing and treatment fees depend on contract terms and usage - Quarterly mix shifts affect gross margin comparability - Short-term investments create fair value and OCI movements - Going-concern disclosures reflect liquidity assumptions --- *Last updated: 2026-04-29T04:41:40.184145+00:00*